Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Poxel Announces its Participation at Upcoming Investor Conferences: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces its Participation at Upcoming Investor Conferences


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25

Premier, Inc. to Report Fiscal 2024 First-Quarter Results and Host Conference Call on November 7, 2023: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2024 First-Quarter Results and Host Conference Call on November 7, 2023


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 first quarter on Tuesday, November 7, 2023, at approximately 6:30 a.m. ET. The company will

Inogen to Report Third Quarter 2023 Financial Results on November 7, 2023: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen to Report Third Quarter 2023 Financial Results on November 7, 2023


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2023 financial

EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for

Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab): https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq

Savara Announces New Employment Inducement Grant: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces New Employment Inducement Grant


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.



On October 3

LivaNova Board Appoints J. Christopher Barry as New Director: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Board Appoints J. Christopher Barry as New Director


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseaseshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases


Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseaseshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases


Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the

Humana and Denver Health Sign Agreement to Expand Humana’s Medicare Advantage Provider Network in the Denver Area: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana and Denver Health Sign Agreement to Expand Humana’s Medicare Advantage Provider Network in the Denver Area


Humana, a leading health and well-being company, and Denver Health, a comprehensive health and hospital system, have entered into an agreement that broadens access to care for Humana Medicare

Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 2, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement

Pfizer Declares Fourth-Quarter 2023 Dividendhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Declares Fourth-Quarter 2023 Dividend


Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 fourth-quarter 2023 dividend on the company’s common stock, payable December 4, 2023, to holders of the Common

Pfizer Declares Fourth-Quarter 2023 Dividendhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Declares Fourth-Quarter 2023 Dividend


Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 fourth-quarter 2023 dividend on the company’s common stock, payable December 4, 2023, to holders of the Common

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Humana #1 in Customer Satisfaction Among Medicare Advantage Plans in Florida: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana #1 in Customer Satisfaction Among Medicare Advantage Plans in Florida


Leading health and well-being company Humana Inc. (NYSE: HUM) is ranked #1 in Florida in the J.D. Power ranking of Medicare Advantage Member Health Plans. Humana, the largest Medicare Advantage

Poxel Announces its Participation at Upcoming Scientific Conference: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces its Participation at Upcoming Scientific Conference


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

EQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
EQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
EQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
Vistagen Announces Pricing of $100 Million Underwritten Offering: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Announces Pricing of $100 Million Underwritten Offering


Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression

Novocure to Report Third Quarter 2023 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Report Third Quarter 2023 Financial Results


Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new clinical study outcomes that further demonstrate the benefits

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new clinical study outcomes that further demonstrate the benefits